Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19

Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19

Background. Severe forms of COVID-19 are associated with the development of a cytokine storm that is characterized by an increased secretion of anti-inflammatory cytokines. Thus, one of the leading strategies of treatment for patients with severe forms of COVID-19 is a decrease in the concentration...

Full description

Saved in:
Bibliographic Details
Main Authors: O. V. Zhukova, A. L. Khokhlov
Format: Article
Language:Russian
Published: IRBIS LLC 2021-04-01
Series:Фармакоэкономика
Subjects:
severe form of covid-19
dexamethasone
tocilizumab
attribute-based statistics
clinical constituent of therapy
economic constituent of therapy
markov’s modeling
inter-drug interaction
beta-distribution of clinical outcomes
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/483
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmacoeconomics.ru/jour/article/view/483

Similar Items